Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals, announced on Monday that it has named Shulamit Ron-Bigger, PhD, as its new chief operating officer (COO).

Dr Ron-Bigger has held the position of head of Strategy and Operations for the Research and Early Development organisation at Bristol Myers Squibb. She has previously served in different commercial and strategy roles including World-Wide Oncology Early Assets, where she managed global commercialisation strategies and co-led an oncology development working group.

Matthew Roden, PhD, Aktis Oncology president and CEO, said, 'I am excited to have a high-impact leader such as Shulamit join Aktis' senior leadership team. Shulamit's deep expertise across multiple domains of biopharma operations spanning strategy, R&D, and commercialisation will be invaluable in our advancement of a broad pipeline of targeted alpha radiopharmaceuticals focused on large patient populations. We thank Brian for his contributions to the extraordinary progress Aktis has made in only two years of existence, and look forward to his continued impact as CBO.'